sociated with treating fibroids, and the methods by 
which fibroids may be prevented in these women 
available. 
(9) Symptomatic uterine fibroids can cause 
heavy menstrual bleeding, pain, and reproductive 
problems, including infertility. Women with uterine 
fibroids are much more likely to miscarry during 
early pregnancy than women without them. 
(10) According to the Evidence Report Sum-
mary on the Management of Uterine Fibroids, as 
compiled by the Agency for Healthcare Research and 
Quality of the Department of Health and Human 
Services, there is a ‘‘remarkable lack of high-quality 
evidence supporting the effectiveness of most inter-
ventions for symptomatic fibroids’’. 
(11) The presence of symptomatic uterine 
fibroids 
is 
the 
most 
common 
reason 
for 
hysterectomies, accounting for approximately one- 
third of hysterectomies, or 200,000 procedures an-
nually. Twenty-two percent of African-American 
women and 7 percent of Caucasian women have 
hysterectomies as a result of uterine fibroids. Lack 
of patient and provider awareness of less invasive al-
ternatives to hysterectomies lead to an estimated 
80,000 to 120,000 unnecessary hysterectomies an-
VerDate Sep 11 2014 
18:26 Apr 09, 2020
Jkt 099200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H6383.IH
H6383
pamtmann on DSKBC07HB2PROD with BILLS
nually. Uterine fibroids are also the leading cause of 
hospitalization related to a gynecological disorder. 
(12) The personal and societal costs of uterine 
fibroids in the United States are significant. Uterine 
fibroid tumors have been estimated to cost the 
United States $5,900,000,000 to $34,400,000,000 
annually. The annual direct costs, including surgery, 
hospital admissions, outpatient visits, and medica-
tions, 
were 
estimated 
at 
$4,100,000,000 
to 
$9,400,000,000 annually. Estimated lost work-hour 
costs 
ranged 
from 
$1,550,000,000 
to 
$17,200,000,000 annually. Obstetric outcomes that 
were attributed to fibroid tumors resulted in costs of 
$238,000,000 to $7,760,000,000 annually. 
SEC. 3. RESEARCH WITH RESPECT TO UTERINE FIBROIDS. 
(a) RESEARCH.—The Director of the National Insti-
tutes of Health (in this section referred to as the ‘‘Direc-
tor of NIH’’) shall expand, intensify, and coordinate pro-
grams for the conduct and support of research with re-
spect to uterine fibroids. 
(b) ADMINISTRATION AND COORDINATION.—The Di-
rector of NIH, acting through Director of the Office of 
Research on Women’s Health, shall carry out research 
conducted pursuant to subsection (a), in coordination with 
the appropriate institutes, offices, and centers of the Na-
VerDate Sep 11 2014 
18:26 Apr 09, 2020
Jkt 099200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H6383.IH
H6383
pamtmann on DSKBC07HB2PROD with BILLS
tional Institutes of Health, including the National Insti-
tute of Child Health and Human Development, the Na-
tional Institute of Environmental Health Sciences, the Of-
fice of Women’s Health, the Office of Minority Health, 
and the National Center on Minority Health and Health 
Disparities, and any other relevant Federal agency, as de-
termined by the Director. 
(c) AUTHORIZATION OF APPROPRIATIONS.—For the 
purpose of carrying out this section, there are authorized 
to be appropriated $30,000,000 for each of fiscal years 
2021 through 2025. 
SEC. 4. RESEARCH WITH RESPECT TO MEDICAID COV-
ERAGE OF UTERINE FIBROIDS TREATMENT. 
(a) RESEARCH.—The Administrator of the Centers 
for Medicare & Medicaid Services (referred to in this sec-
tion as the ‘‘Administrator’’) shall expand the Chronic 
Conditions Data Warehouse research database of such 
Centers for Medicare & Medicaid Services to collect data 
on items and services furnished to women diagnosed with 
uterine fibroids and fibroids-related symptoms under a 
State plan (or a waiver of such a plan) under the Medicaid 
program under title XIX of the Social Security Act (42 
U.S.C. 1396 et seq.) or under a State child health plan 
(or a waiver of such a plan) under the Children’s Health 
Insurance Program under title XXI of such Act (42 
VerDate Sep 11 2014 
18:26 Apr 09, 2020
Jkt 099200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H6383.IH
H6383
pamtmann on DSKBC07HB2PROD with BILLS
U.S.C. 1397aa et seq.) for the treatment of such fibroids 
and symptoms for purposes of assessing the frequency at 
which such women are furnished such items and services. 
(b) REPORT.— 
(1) IN GENERAL.—Not later than the date that 
is one year after the date of the enactment of this 
Act, the Administrator shall submit to Congress a 
report on the amount of Federal and State expendi-
tures with respect to items and services furnished 
for the treatment of uterine fibroids and fibroids-re-
lated symptoms under State plans (or waivers of 
such plans) under the Medicaid program under such 
title XIX and State child health plans (or waivers of 
such plans) under the Children’s Health Insurance 
Program under such title XXI. 
(2) COORDINATION.—The Administrator shall 
coordinate the development and submission of the 
report required under paragraph (1) with each of 
the following: 
(A) Within the Centers for Medicare & 
Medicaid Services— 
(i) the Office of Minority Health; 
(ii) the Center for Medicaid and 
CHIP Services; 
VerDate Sep 11 2014 
18:26 Apr 09, 2020
Jkt 099200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H6383.IH
H6383
pamtmann on DSKBC07HB2PROD with BILLS
(iii) the Office of Enterprise Data and 
Analytics; and 
(iv) any other office or center deter-
mined appropriate by the Administrator. 
(B) Any other relevant Federal agency, as 
determined by the Administrator. 
(c) AUTHORIZATION OF APPROPRIATIONS.—For the 
purpose of carrying out this section, there are authorized 
to be appropriated such sums as may be necessary for 
each of the fiscal years 2021 through 2025. 
SEC. 5. EDUCATION AND DISSEMINATION OF INFORMATION 
WITH RESPECT TO UTERINE FIBROIDS. 
(a) UTERINE FIBROIDS PUBLIC EDUCATION PRO-
GRAM.—The Secretary of Health and Human Services, 
acting through the Director of the Centers for Disease 
Control and Prevention, shall develop and disseminate to 
the public information regarding uterine fibroids, includ-
ing information on— 
(1) the awareness, incidence, and prevalence of 
uterine fibroids among women, including all minority 
women; 
(2) the elevated risk for minority women to de-
velop uterine fibroids; and 
(3) the availability, as medically appropriate, of 
the range of treatment options for symptomatic 
VerDate Sep 11 2014 
18:26 Apr 09, 2020
Jkt 099200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H6383.IH
H6383
pamtmann on DSKBC07HB2PROD with BILLS
uterine fibroids, including non-hysterectomy treat-
ments and procedures. 
(b) DISSEMINATION
OF INFORMATION.—The Sec-
retary may disseminate information under subsection (a) 
directly or through arrangements with intra-agency initia-
tives, nonprofit organizations, consumer groups, institu-
tions of higher education (as defined in section 101 of the 
Higher Education Act of 1965 (20 U.S.C. 1001)), or Fed-
eral, State, or local public private partnerships. 
(c) AUTHORIZATION OF APPROPRIATIONS.—For the 
purpose of carrying out this section, there are authorized 
to be appropriated such sums as may be necessary for 
each of fiscal years 2021 through 2025. 
SEC. 6. INFORMATION TO HEALTH CARE PROVIDERS WITH 
RESPECT TO UTERINE FIBROIDS. 
(a) DISSEMINATION
OF INFORMATION.—The Sec-
retary of Health and Human Services, acting through the 
Administrator of the Health Resources and Services Ad-
ministration and the Director of the Agency for 
Healthcare Research and Quality shall, in consultation 
and in accordance with guidelines from relevant medical 
societies, develop and disseminate to health care providers 
information on uterine fibroids for the purpose of ensuring 
that health care providers remain informed about current 
information on uterine fibroids. Such information shall in-
VerDate Sep 11 2014 
18:26 Apr 09, 2020
Jkt 099200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6201
E:\BILLS\H6383.IH
H6383
pamtmann on DSKBC07HB2PROD with BILLS
clude the elevated risk for minority women to develop uter-
ine fibroids and the range of available options for the 
treatment of symptomatic uterine fibroids, including non- 
hysterectomy drugs and devices approved under the Fed-
eral Food, Drug, and Cosmetic Act. 
(b) AUTHORIZATION OF APPROPRIATIONS.—For the 
purpose of carrying out this section, there are authorized 
to be appropriated such sums as may be necessary for 
each of the fiscal years 2021 through 2025. 
SEC. 7. DEFINITION. 
In this Act, the term ‘‘minority women’’ means 
women who are members of a racial and ethnic minority 
group, as defined in section 1707(g) of the Public Health 
Service Act (42 U.S.C. 300u–6(g)). 
Æ 
VerDate Sep 11 2014 
18:26 Apr 09, 2020
Jkt 099200
PO 00000
Frm 00010
Fmt 6652
Sfmt 6301
E:\BILLS\H6383.IH
H6383
pamtmann on DSKBC07HB2PROD with BILLS